Pancreatic Cancer Research

ResearcherJichi Medical UniversityActive in the last 2 years

Noriyoshi Fukushima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4522-9007; OpenAlex author ID A5005202372. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 10

  1. A modified CAP-based grading system incorporating non-tubular components for prognostic stratification in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00428-026-04731-8↗
  2. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  3. Pancreatic Ductal Adenocarcinoma with Autoimmune Pancreatitis: A Case Report and Literature Review. Co-author DOI 10.2169/internalmedicine.4361-24↗
  4. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasoun… Co-author DOI 10.1007/s00428-021-03236-w↗
  5. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  6. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  7. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy. Co-author DOI 10.1038/s41598-021-87748-0↗
  8. Is an atypical flat lesion (AFL) a precursor lesion of the pancreatic ductal adenocarcinoma in human? Last author DOI 10.1111/pin.12670↗
  9. [Molecular genetics of pancreatic ductal adenocarcinoma]. Co-author PMID 25856977↗
  10. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. Co-author DOI 10.1007/s00535-011-0482-y↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Kanno · 3 shared papers, 2022–2026 · strength 0.62
  2. Naoki Sano · 2 shared papers, 2025–2026 · strength 0.52
  3. Kenichi Hirabayashi · 3 shared papers, 2021–2025 · strength 0.38
  4. Toru Furukawa · 3 shared papers, 2021–2025 · strength 0.38
  5. Hironori Yamamoto · 1 shared paper, 2025 · strength 0.23
  6. Yusuke Sakurai · 1 shared paper, 2025 · strength 0.23
  7. Naohiro Sata · 1 shared paper, 2025 · strength 0.23
  8. Masanobu Taguchi · 1 shared paper, 2025 · strength 0.23
  9. Takashi Hatori · 1 shared paper, 2025 · strength 0.19
  10. Sohei Satoi · 1 shared paper, 2025 · strength 0.19
  11. Shinichi Egawa · 1 shared paper, 2025 · strength 0.19
  12. Yohei Masugi · 1 shared paper, 2025 · strength 0.19
  13. Yoshifumi Takeyama · 1 shared paper, 2025 · strength 0.19
  14. Haruyoshi Tanaka · 1 shared paper, 2025 · strength 0.19
  15. Yuichi Nagakawa · 1 shared paper, 2025 · strength 0.19
  16. Makoto Ueno · 1 shared paper, 2025 · strength 0.19
  17. Masaji Tani · 1 shared paper, 2025 · strength 0.19
  18. Michiaki Unno · 1 shared paper, 2025 · strength 0.19
  19. Tsutomu Fujii · 1 shared paper, 2025 · strength 0.19
  20. Takao Itoi · 1 shared paper, 2025 · strength 0.19
  21. Olca Baştürk · 2 shared papers, 2021–2022 · strength 0.19
  22. Boris V. Janssen · 2 shared papers, 2021–2022 · strength 0.19
  23. Chanjuan Shi · 2 shared papers, 2021–2022 · strength 0.19
  24. Volkan N. Adsay · 2 shared papers, 2021–2022 · strength 0.19
  25. Huamin Wang · 2 shared papers, 2021–2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.